3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Myeloid
1
Lymphoid
1
Conditions
Precursor Cell Lymphoblastic Leukemia-Lymphoma
2
Myelodysplastic Syndromes
2
Myeloproliferative Disorders
1
Lymphoma
1
Leukemia, Myelomonocytic, Juvenile
1
Leukemia, Myelomonocytic, Chronic
1
Leukemia, Myelomonocytic, Acute
1
Leukemia, Myeloid, Acute
1
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
1
Leukemia, Biphenotypic, Acute
1
Graft vs Host Disease
1
Interventions
Cytarabine
89
Daunorubicin
45
Azacitidine
43
Idarubicin
27
venetoclax
26
fludarabine
26
Etoposide
25
Cyclophosphamide
25
Mitoxantrone
22
Decitabine
19
Busulfan
19
Methotrexate
16
Gemtuzumab
14
Granulocyte Colony-Stimulating Factor
12
Whole-Body Irradiation
10
Peripheral Blood Stem Cell Transplantation
10
Melphalan
10
gilteritinib
9
Filgrastim
9
fludarabine phosphate
8
Tacrolimus
8
Mycophenolic Acid
8
Cyclosporine
8
Tretinoin
7
Radiotherapy
7
Drug Therapy
7
Observation
6
Homoharringtonine
6
Antilymphocyte Serum
6
quizartinib
5
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 3
×
Leukemia, Myeloid, Acute
×
Calcineurin Inhibitors
×
Clear all
NCT01749111
2017-03-03
CICLODECH
Hospital Israelita Albert Einstein
Phase 3
Terminated
3 enrolled